Wall Street analysts expect Acer Therapeutics (NASDAQ:ACER) to announce ($0.69) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Acer Therapeutics’ earnings, with estimates ranging from ($0.72) to ($0.66). Acer Therapeutics reported earnings per share of ($1.24) in the same quarter last year, which would suggest a positive year-over-year growth rate of 44.4%. The company is scheduled to announce its next quarterly earnings report on Friday, May 11th.
On average, analysts expect that Acer Therapeutics will report full year earnings of ($3.22) per share for the current year, with EPS estimates ranging from ($3.72) to ($2.83). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.55) per share, with EPS estimates ranging from ($2.81) to ($2.07). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Acer Therapeutics.
Acer Therapeutics (NASDAQ:ACER) last posted its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.10).
NASDAQ ACER traded down $0.22 during trading on Thursday, reaching $18.99. 20,934 shares of the company’s stock traded hands, compared to its average volume of 25,915. The company has a market capitalization of $140.58, a price-to-earnings ratio of -4.92 and a beta of 2.31. Acer Therapeutics has a 12-month low of $5.69 and a 12-month high of $22.63.
Large investors have recently added to or reduced their stakes in the company. Ardsley Advisory Partners acquired a new stake in Acer Therapeutics in the 4th quarter worth approximately $212,000. Stonepine Capital Management LLC acquired a new stake in Acer Therapeutics in the 4th quarter worth approximately $1,385,000. J. Goldman & Co LP acquired a new stake in Acer Therapeutics in the 4th quarter worth approximately $1,496,000. Finally, Perceptive Advisors LLC acquired a new stake in Acer Therapeutics in the 4th quarter worth approximately $2,091,000. Institutional investors and hedge funds own 7.41% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3385456/zacks-brokerages-expect-acer-therapeutics-acer-will-announce-earnings-of-0-69-per-share.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.